Literature DB >> 8816848

Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions.

H A Kleinveld1, P F Duif, H L Pekelharing, H J van Rijn.   

Abstract

Increased plasma concentrations of lipoprotein(a) (Lp(a)) are associated with an increased risk for atherosclerotic cardiovascular disease. It is thought that the atherogenicity of Lp(a) is mediated both through its LDL-like properties and its plasminogen-like properties. In this study we have investigated the LDL-like atherogenic properties of Lp(a) by comparing the susceptibility to in vitro oxidation of Lp(a) and LDL isolated from the same subject. The subjects studied varied widely in plasma Lp(a) concentration (331-1829 mg/l) and Lp(a) phenotype (from B to S4). Lipoproteins are notoriously unstable in vitro, consequently differences in in vitro handling could influence oxidizability. Therefore, the isolation and handling of Lp(a) and LDL were performed in an identical fashion. Lp(a) and LDL containing fractions were obtained by density gradient ultracentrifugation. Separate fractions containing various amounts of Lp(a) and LDL, quantitated by measuring both Lp(a) and apo B-100, were subsequently oxidized on equimolar apo B-100 basis. Despite large differences in the Lp(a)/apo B-100 ratio of the various fractions (ranging from 5.3 +/- 1.7 to 0.2 +/- 0.1) they showed quite similar oxidation characteristics. The most dense Lp(a) containing fractions showed an aberrant susceptibility to oxidation. Subsequent gel filtration and reconstitution experiments showed that this was due to protein (i.e., albumin) contamination. Removal of excess protein revealed an oxidation pattern similar to that of LDL. It is concluded that the susceptibility of Lp(a) to lipid-peroxidation is similar to that of LDL when isolated simultaneously and in the same way from the same subject. Thus, lipid-peroxidation of Lp(a) is not influenced by the presence of its distinguishing apolipoprotein(a).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816848     DOI: 10.1016/0005-2760(96)00055-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Serum lipids and lipoproteins in clinically healthy male Camels (Camelus dromedarius).

Authors:  S Nazifi; H R Gheisari; M A Poorkabir; S Saadatfar
Journal:  Vet Res Commun       Date:  2000-12       Impact factor: 2.459

2.  Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.

Authors:  Rudel A Saunders; Kazuyuki Fujii; Leah Alabanza; Roald Ravatn; Tsunekazu Kita; Kazuya Kudoh; Masahiro Oka; Khew-Voon Chin
Journal:  Biochem Pharmacol       Date:  2010-04-21       Impact factor: 5.858

3.  A phospholipidomic analysis of all defined human plasma lipoproteins.

Authors:  Monireh Dashti; Willem Kulik; Frans Hoek; Enno C Veerman; Maikel P Peppelenbosch; Farhad Rezaee
Journal:  Sci Rep       Date:  2011-11-07       Impact factor: 4.379

4.  Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients.

Authors:  Jim Joseph; Farzana Ganjifrockwala; Grace George
Journal:  Oxid Med Cell Longev       Date:  2016-10-19       Impact factor: 6.543

5.  MicroRNA-148a regulates low-density lipoprotein metabolism by repressing the (pro)renin receptor.

Authors:  Na Wang; Lishu He; Hui Lin; Lunbo Tan; Yuan Sun; Xiaoying Zhang; A H Jan Danser; Hong S Lu; Yongcheng He; Xifeng Lu
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.